Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.

Abstract

OBJECTIVES Whether new biomarkers contribute significantly to the existing, simple noninvasive test (comprising of routine laboratory parameters such as the AST to platelet ratio index (APRI)) for predicting liver fibrosis remains unknown. METHODS We measured 7 biomarkers in 91 patients with chronic hepatitis C (CHC): haptoglobin, apolipoprotein A1, α2-macroglobulin, hyaluronic acid, type III procollagenic peptide, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1. RESULTS The "multibiomarker" score (based on regression coefficients of significant biomarkers) is an independent predictive factor for significant fibrosis [APRI-adjusted odds ratio, 2.41 (95% CI, 1.28 to 4.55)]. However, the incorporation of the multibiomarker score into the APRI resulted in only a small diagnostic improvement [0.83 (95% CI, 0.74 to 0.92) vs. 0.79 (0.69 to 0.89); p=0.19]. CONCLUSIONS For assessing significant fibrosis in individual CHC patients, the 7 contemporary biomarkers that we studied add only modestly to the readily available, simple noninvasive index.

DOI: 10.1016/j.clinbiochem.2011.08.1151

Statistics

020040020132014201520162017
Citations per Year

205 Citations

Semantic Scholar estimates that this publication has 205 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Park2011DiagnosticVO, title={Diagnostic value of multiple biomarker panel for prediction of significant fibrosis in chronic hepatitis C.}, author={Seung Ha Park and Chang Hoon Kim and Dong Joon Kim and Ki Tae Suk and Jong Ha Park and Jae Youn Cheong and Sung Won Cho and Seong Gyu Hwang and Youn Jae Lee and Mong Cho and Jin Mo Yang and Ha Young Park and Young Bae Kim}, journal={Clinical biochemistry}, year={2011}, volume={44 17-18}, pages={1396-9} }